HOXC6 in the prognosis of prostate cancer
Source abstract
Abstract
Aims Our study aimed to investigate the expression and prognostic role of homeobox C6 (HOXC6) in prostate cancer (PCa).Methods Relative expression of HOXC6 at mRNA and protein levels in tissues and cell lines of PCa were measured using quantitative real-time polymerase chain reaction (qRT-PCR) and Western blot analysis, respectively. Association between HOXC6 expression and clinical factors was analyzed by Chi-square test. HOXC6 effects on the proliferation, invasion and metastasis of PCa cells were severally examined through CCK-8 and transwell assays.Results Relative expressions of HOXC6 at mRNA and protein levels were obviously higher in both PCa tissues and cells than in adjacent non-cancerous tissues and normal human prostate epithelial cells (p < .05). Chi-square test demonstrated that high expression of HOXC6 was significantly associated with PSA concentration, Gleason score and TNM stage (p < .05). The down-regulation of HOCX6 remarkably inhibited the proliferation, migration and invasion of PCa cells. Kaplan-Meier analysis showed that patients with high HOXC6 expression had shorter overall survival than those with low HOXC6 expression (log rank test, p < .001).Conclusion Up-regulated HOXC6, in PCa patients, could not only participate in the progression of PCa but also function as an independent prognostic marker for the cancer.
Source: openalex_inverted_index · Quality: baseline
Research context
OpenAlex topics: RNA Research and Splicing · RNA modifications and cancer · Cancer-related gene regulation
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
Affiliations
Lihuili Hospital
Precision Medicine Center, The First Hospital of Handan City
Department of Oncology, The Second Medical Center, Chinese PLA General Hospital
School of Safety Engineering, China University of Labor Relations
Affiliated People's Hospital of Inner Mongolia Medical University
References (34)
Show source-provided references
1. 10.1016/j.eururo.2012.02.05410.1016/j.eururo.2012.02.054 ↗
2. 10.1080/01635581.2013.81222510.1080/01635581.2013.812225 ↗
3. 10.3322/caac.2116610.3322/caac.21166 ↗
4. 10.1002/cncr.2860910.1002/cncr.28609 ↗
5. 10.3322/caac.2120810.3322/caac.21208 ↗
6. 10.3109/07357907.2013.80009510.3109/07357907.2013.800095 ↗
7. 10.14348/molcells.2015.227210.14348/molcells.2015.2272 ↗
8. 10.3322/caac.2010710.3322/caac.20107 ↗
9. 10.1007/s10552-013-0249-210.1007/s10552-013-0249-2 ↗
10. 10.1016/j.juro.2014.06.07510.1016/j.juro.2014.06.075 ↗
11. 10.12659/MSM.89124710.12659/MSM.891247 ↗
12. 10.1210/en.2006-125010.1210/en.2006-1250 ↗
13. 10.1038/srep0217810.1038/srep02178 ↗
14. 10.1016/j.bbagrm.2015.02.00310.1016/j.bbagrm.2015.02.003 ↗
15. Bodey B, Bodey B, Jr., Siegel SE, et al. Immunocytochemical detection of the homeobox B3, B4, and C6 gene products in breast carcinomas. Anticancer Res. 2000;20:3281–3286.
16. 10.1016/j.jmb.2011.05.05010.1016/j.jmb.2011.05.050 ↗
17. 10.1074/jbc.M112.36167510.1074/jbc.M112.361675 ↗
18. 10.1053/j.gastro.2008.06.03410.1053/j.gastro.2008.06.034 ↗
19. Bodey B, Bodey B, Jr,., Siegel SE, et al. Homeobox B3, B4, and C6 gene product expression in osteosarcomas as detected by immunocytochemistry. Anticancer Res. 2000;20:2717–2721.
20. 10.1182/blood.V87.5.1737.173710.1182/blood.V87.5.1737.1737 ↗
21. 10.1002/pros.2306510.1002/pros.23065 ↗
22. 10.1038/sj.onc.120790610.1038/sj.onc.1207906 ↗
23. 10.3390/ijms1602385610.3390/ijms16023856 ↗
24. 10.1155/2014/59170310.1155/2014/591703 ↗
25. 10.12659/MSM.89308310.12659/MSM.893083 ↗
26. 10.1002/pros.2294210.1002/pros.22942 ↗
27. 10.1186/s12881-014-0143-010.1186/s12881-014-0143-0 ↗
28. 10.18632/oncotarget.269110.18632/oncotarget.2691 ↗
29. 10.1186/1477-7819-12-28410.1186/1477-7819-12-284 ↗
30. 10.3109/07357907.2015.104164110.3109/07357907.2015.1041641 ↗
31. 10.3390/cancers304371410.3390/cancers3043714 ↗
32. 10.1242/dev.12688810.1242/dev.126888 ↗
33. 10.1016/j.jss.2014.01.01710.1016/j.jss.2014.01.017 ↗
34. 10.4149/neo_2013_05710.4149/neo_2013_057 ↗